United States Thyroid Gland Disorders Therapeutics Market 2025 | Growth Drivers, Competitive Landscape & Investment Opportunities

Market Size and Growth

Global Thyroid Gland Disorders Therapeutics Market reached US$ 2.7 billion in 2023 and is expected to reach US$ 4.3 billion by 2031, growing at a CAGR of 6.3% during the forecast period 2024-2031

Key Development:

United States: Recent Industry Developments

✅ In September 2025, Viridian Therapeutics announced the completion of enrollment in both the REVEAL clinical trials for VRDN-003. These pivotal trials aim to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic thyroid eye disease (TED).

✅ In August 2025, UNC Lineberger Comprehensive Cancer Center launched a groundbreaking clinical trial aimed at improving outcomes for patients with BRAF wildtype anaplastic thyroid cancer (ATC), a rare and aggressive form of thyroid cancer. This trial represents a significant step forward in treating a patient population with limited effective treatment options

✅ In July 2025, Viridian Therapeutics entered into a collaboration and license agreement with Kissei Pharmaceutical to develop and commercialize veligrotug and VRDN-003 in Japan.

✅ In June 2025, a study by the University of Texas Medical Branch (UTMB) suggested that combination thyroid therapy may reduce dementia and mortality risk in hypothyroidism. The research indicates that combining levothyroxine with other thyroid hormones could offer additional benefits for patients with hypothyroidism.

✅ In May 2025, the American Thyroid Association (ATA) reaffirmed its stance on synthetic levothyroxine as the standard therapy for hypothyroidism. The ATA emphasized that levothyroxine is safe and effective, and it remains the recommended treatment for the condition.

✅ In May 2025, Viridian Therapeutics received FDA Breakthrough Therapy Designation for veligrotug, an anti-IGF-1R antibody targeting TED. This designation underscores the drug's potential to significantly improve treatment outcomes for TED patients.

✅ In April 2025, the U.S. Food and Drug Administration (FDA) sent letters to manufacturers, importers, and distributors of unapproved animal-derived thyroid medications, notifying them of the agency's intent to take action against these products. The FDA urged patients to consult their healthcare providers to transition to FDA-approved thyroid hormone replacement medications.

Japan: Recent Industry Developments

✅ In August 2025, Viridian Therapeutics received an upfront payment of $70 million from Kissei Pharmaceutical as part of their collaboration to develop and commercialize veligrotug and VRDN-003 in Japan. The agreement also includes up to $315 million in milestone payments and tiered royalties on net sales.

✅ In July 2025, Viridian Therapeutics and Kissei Pharmaceutical entered into a $70 million collaboration and license agreement to develop and commercialize veligrotug and VRDN-003 in Japan. This partnership aims to address the unmet needs of TED patients in the region.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/thyroid-gland-disorders-therapeutics-market?sb

Thyroid gland disorders therapeutics refer to treatments designed to manage conditions affecting the thyroid, such as hypothyroidism, hyperthyroidism, and thyroid cancer. These include hormone replacement, antithyroid drugs, and targeted therapies, which help restore hormonal balance, control disease progression, and improve patient quality of life.

Recent Mergers and acquisitions:

United States: Recent M&A Activity

✅ In October 2025, BioCryst Pharmaceuticals announced its acquisition of Astria Therapeutics in a cash-and-stock deal valued at approximately $700 million. The acquisition adds Astria's lead drug candidate, navenibart, an injectable therapy in late-stage trials targeting hereditary angioedema (HAE), to BioCryst's pipeline.

✅ In May 2025, Alumis acquired Acelyrin in an all-stock transaction valued at approximately $737 million, forming a combined clinical-stage biopharma focused on immune-mediated diseases. Acelyrin's lead asset, lonigutamab, is a Phase II IGF-1 receptor antagonist for thyroid eye disease.

Japan: Recent M&A Activity

✅ In July 2025, Viridian Therapeutics entered into a collaboration and license agreement with Kissei Pharmaceutical to develop and commercialize veligrotug and VRDN-003 in Japan. The agreement includes a $70 million upfront payment and up to $315 million in milestone payments.

Key Players:

=> GlaxoSmithKline PLC, Abbvie Inc,Amgen Inc, Novartis AG, Mylan NV, Merck KGaA, Pfizer Inc, Takeda Pharmaceutical Company Limited, Elexis Inc, IBSA Pharma (IBSA Group) among others.

Growth Forecast Projected:

The Global Thyroid Gland Disorders Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Thyroid Gland Disorders Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=thyroid-gland-disorders-therapeutics-market

Key Segments:

➥ By Disease Type: Hypothyroidism, Hyperthyroidism, Others

➥ By Drug Class: Thiourea Derivatives, Propylthiouracil (PTU), Thyroid Hormones, Electrolytes, Corticosteroids, Tricyclic Antidepressants, Antiepileptic Agents

➥ By Route of Administration: Oral, Parenteral, Others

➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis for Thyroid Gland Disorders Therapeutics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Thyroid Gland Disorders Therapeutics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Thyroid Gland Disorders Therapeutics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/thyroid-gland-disorders-therapeutics-market?sb

FAQ

What is the current size of the Thyroid Gland Disorders Therapeutics Market?

A: In 2023, the Thyroid Gland Disorders Therapeutics Market was valued at US$ 2.7 billion , reflecting its strong industry presence.

Q2: How large is the Thyroid Gland Disorders Therapeutics Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Thyroid Gland Disorders Therapeutics Market will grow to around US$ 4.3 billion, demonstrating significant expansion.

Q3: What is the growth rate of the Thyroid Gland Disorders Therapeutics Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 6.3% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.